3-(N-叔丁氧羰基氨基)苯甲酸 | 111331-82-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(N-叔丁氧羰基氨基)苯甲酸
• 中文别名: 3-(叔丁氧羰基氨基)苯甲酸；3-(BOC-氨基)苯甲酸；N-BOC-3-氨基苯甲酸
• 英文名称: 3-((tert-butoxycarbonyl)amino)benzoic acid
• 英文别名: 3-(boc-amino)benzoic acid；Boc-3-aminobenzoic acid；3-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid
• CAS: 111331-82-9
• 化学式: C₁₂H₁₅NO₄
• mdl: MFCD00235884
• 分子量: 237.255
• InChiKey: SAPAUOFSCLCQJB-UHFFFAOYSA-N

物化性质

• 熔点：
  195 °C (dec.)
• 沸点：
  339.8±25.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格使用和储存，通常不会发生分解，也未发现已知的危险反应。应避免与强氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  29242990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将贮藏器密封保存，在阴凉、干燥处存放，并确保工作环境有良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-3-aminobenzoic acid
Synonyms: 3-[(tert-Butoxycarbonyl)amino]benzoic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-3-aminobenzoic acid
CAS number: 111331-82-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H15NO4
Molecular weight: 237.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(N-叔丁氧羰基氨基)苯甲酸 在 盐酸 、 sodium azide 、 sodium hydride 作用下， 以 二氯甲烷 、 乙酸乙酯 、 丙酮 、 甲苯 为溶剂， 反应 10.0h， 生成 N-[(3R)-1-(3,3-二甲基-2-氧代丁基)-2,3-二氢-2-氧代-5-(2-吡啶基)-1H-1,4-苯并二氮杂卓-3-基]-N’-[3-(甲基氨基)苯基]脲
  参考文献：
  名称：

  （3R）-N-（1-（叔丁基羰基甲基）-2,3-二氢-2-氧代-5-（2-吡啶基）-1H-1,4-苯并二氮杂-3-基）-N'- （3-（甲基氨基）苯基）脲（YF476）：一种有效的口服活性胃泌素/ CCK-B拮抗剂。

  摘要：

  已合成了许多与原型类似物L-365,260（更接近于最近报道的化合物YM022）有关的新的1,4-苯并二氮杂-2-酮基胃泌素/ CCK-B受体拮抗剂，并对其生物学活性进行了评估。筛选了化合物抑制[125I] CCK-8与大鼠脑中胃泌素/ CCK-B受体结合的能力以及[3H] L-364718与大鼠胰腺中CCK-A受体结合的抑制能力，并显示了是胃泌素/ CCK-B受体的有效和选择性配体。体内功能研究证明了该化合物是该受体的拮抗剂，这是由于它们在麻醉的大鼠中具有抑制五肽胃泌素诱导的胃酸分泌的能力所证明的。体内更广泛的评估包括在大鼠酸分泌模型中确定所选化合物的ED50值，以及检查这些化合物对口服和静脉内给药后Heidenhain袋狗中五肽胃泌素诱导的胃酸分泌的影响。两种化合物，即（3R）-N- [1-[（叔丁基羰基）甲基] -2,3-二氢-2-氧代-5-（2-吡啶基）-1H-1,4-苯并二氮杂-3

  DOI：

  10.1021/jm960669+
• 作为产物：
  描述：

  间氨基苯甲酸 在 氯化亚砜 、 水 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 27.0h， 生成 3-(N-叔丁氧羰基氨基)苯甲酸
  参考文献：
  名称：

  用于开发有效，可逆和选择性单酰基甘油脂肪酶（MAGL）抑制剂的4-氯苯甲酰基哌啶衍生物的结构优化

  摘要：

  单酰基甘油脂肪酶（MAGL）抑制剂被认为是各种病理状况（包括几种癌症）的潜在治疗剂。文献中报道了许多MAGL抑制剂。然而，它们大多数显示出不可逆的作用机理，这引起了重要的副作用。迄今为止，可逆的MAGL抑制剂的使用仅得到了部分研究，这主要是由于缺乏具有良好的MAGL可逆抑制特性的化合物。在这项研究中，我们从显示可逆的MAGL抑制机制（K i = 8.6μM）的（4-（4-氯苯甲酰基）哌啶-1-基）（4-甲氧基苯基）甲酮（CL6a）铅化合物开始，我们开始对其结构进行优化，我们开发了一种新的高效选择性MAGL抑制剂（17b，K i = 0.65μM）。此外，建模研究表明，该化合物的结合相互作用取代了在MAGL结合位点复制其H键的结构水分子，从而为开发新的MAGL抑制剂确定了新的关键锚点。

  DOI：

  10.1021/acs.jmedchem.6b01459

文献信息

• Water soluble multi-biotin-containing compounds
  申请人：Wilbur Scott D.

  公开号：US20060228325A1

  公开（公告）日：2006-10-12

  Water-soluble discrete multi-biotin-containing compounds with at least three (3) biotin moieties are disclosed. The water-soluble biotin-containing compounds may additionally comprise one or more moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compounds may include a reactive moiety that provides a site for reaction with yet another moiety, such as a targeting, diagnostic or therapeutic functional moiety. Biotinylation reagents comprising water-soluble linker moieties are also disclosed and may additionally comprise a biotinidase protective group. Methods for amplifying the number of sites for binding biotin-binding proteins at a selected target using multi-biotin compounds also are disclosed.

  可溶于水的离散多生物素含有化合物，至少含有三个（3）生物素基团。这些可溶于水的生物素含有化合物可能还包括一个或多个使其对生物素酶的裂解具有抗性的基团，或者在体外或体内可被裂解的基团。这些离散的多生物素含有化合物可能包括一个反应性基团，提供与另一个基团（如靶向、诊断或治疗功能基团）反应的位点。还公开了包含可溶于水的连接基团的生物素化试剂，可能还包括生物素酶保护基团。还公开了使用多生物素化合物扩增在选定靶点上结合生物素结合蛋白的位点数量的方法。
• Cyclopentyl sulfonamide derivatives
  申请人：Eli Lilly and Company

  公开号：US06639107B1

  公开（公告）日：2003-10-28

  The present invention provides certain cyclopentyl sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a mammal. It also relates to novel cyclopentyl sulfonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.

  本发明提供了某些式(I)的环戊基磺酰胺衍生物，用于增强哺乳动物中谷氨酸受体的功能。它还涉及新颖的环戊基磺酰胺衍生物，以及它们的制备方法和含有它们的药物组合物。
• [EN] AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126731A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为：(I)，其中A、B、R1、X1、X2和W如本文所述。
• Selective reduction of carboxylic acids to aldehydes with hydrosilane via photoredox catalysis
  作者：Muliang Zhang、Nan Li、Xingyu Tao、Rehanguli Ruzi、Shouyun Yu、Chengjian Zhu

  DOI：10.1039/c7cc05570f

  日期：——

  The direct reduction of carboxylic acids to aldehydes with hydrosilane was achieved through visible light photoredox catalysis. The combination of both single electron transfer and hydrogen atom transfer steps offers a novel and convenient approach to selective reduction of carboxylic acids to aldehydes. The method also features mild conditions, high yields, broad substrate scope, and good functional

  通过可见光光氧化还原催化可将羧酸与氢硅烷直接还原为醛。单电子转移步骤和氢原子转移步骤的结合提供了一种新颖且方便的方法，用于将羧酸选择性还原为醛。该方法还具有温和的条件，高收率，广泛的底物范围和良好的官能团耐受性，例如炔烃基，酯基，酮基，酰胺基和胺基。
• Carboxylation of Aryl Triflates with CO₂ Merging Palladium and Visible-Light-Photoredox Catalysts
  作者：Samir Kumar Bhunia、Pritha Das、Shantanu Nandi、Ranjan Jana

  DOI：10.1021/acs.orglett.9b01532

  日期：2019.6.21

  visible-light-promoted, highly practical carboxylation of readily accessible aryl triflates at ambient temperature and a balloon pressure of CO2 by the combined use of palladium and photoredox Ir(III) catalysts. Strikingly, the stoichiometric metallic reductant is replaced by a nonmetallic amine reductant providing an environmentally benign carboxylation process. In addition, one-pot synthesis of a carboxylic

  我们在此报告了在环境温度和CO 2的球囊压力下，易于获得的芳基三氟甲磺酸酯在可见光促进下的高度实用的羧化反应钯和光氧化还原Ir（III）催化剂的组合使用。令人惊讶的是，化学计量的金属还原剂被非金属的胺还原剂所替代，从而提供了对环境无害的羧化过程。另外，通过后期羧化反应已经完成了直接从苯酚的一锅法合成羧酸和雌酮的修饰以及药用药物阿达帕林和贝沙罗汀的简明合成。此外，已经在H型密闭容器中证明了平行的脱羧-羧化反应，这对战略领域是一个有趣的概念。光谱和光谱电化学研究表明，电子从Ir（III）/ DIPEA组合中转移，生成了芳基羧酸盐和Pd（0）用于催化转换。